On October 9, Tempus AI rose 5.2% in regular trading, reaching $72.65/share with turnover of $136 million. The catalyst was the company's announcement that it has expanded its multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, an individualized cancer therapy being tested with Keytruda in melanoma and other cancers.

Under the expanded agreement, Tempus will manage tumor tissue and blood sample collection, transfer for sequencing, and provide next-generation sequencing services to support the therapy's design and manufacturing. Financial terms were not disclosed. This expansion positions Tempus as a core supplier in precision oncology sequencing services, reinforcing its role in the individualized cancer treatment ecosystem.

The stock's movement comes despite a mixed sector backdrop. Among peers in the Life Sciences Tools & Services sector, 10x Genomics rose 9.19%, Illumina gained 3.45%, Thermo Fisher Scientific added 0.87%, Danaher climbed 1.23%, and Waters advanced 1.28%.